Home > Insider Trading > Filing (0001104659-24-114409)

Filing Details

Accession Number:: 0001104659-24-114409
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2024-11-05 17:40:42
Reporting Period:: 2024-11-01

Accepted Time:: 2024-11-05 17:40:42
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1657312	Verona Pharma Plc	VRNA	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1408502	W Mark Hahn	3 More London Riverside London X0 SE1 2RE	Chief Financial Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Ordinary Shares	Disposition	2024-11-01	48,888	$4.38	14,374,520	No	4	S	Direct
Ordinary Shares	Disposition	2024-11-04	80,784	$4.39	14,293,736	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct
No	4	S	Direct

Footnotes

Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.
The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 instruction adopted on March 6, 2024.
The price reported represents a weighted average price of the ADSs divided by eight (8). The securities were sold in multiple transactions at prices ranging from $4.375 to $4.3825 per Ordinary Share, inclusive (or $35.00 to $35.06 per ADS, inclusive). The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
The price reported represents a weighted average price of the ADSs divided by eight (8). The securities were sold in multiple transactions at prices ranging from $4.375 to $4.4225 per Ordinary Share, inclusive (or $35.00 to $35.38 per ADS, inclusive). The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
Consists of (i) 3,000,000 Ordinary Shares underlying Restricted Share Units, each of which represents a contingent right to receive one (1) Ordinary Share of the Issuer (which are represented by 375,000 ADSs); and (ii) 11,293,736 Ordinary Shares underlying 1,411,717 ADSs.